Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
NA
39 participants
INTERVENTIONAL
2017-10-12
2018-10-03
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group A: PicoPlus for unwanted tattoos.
Subjects receiving PicoPlus laser system treatment for unwanted tattoos.
PicoPlus laser system
Laser treatment using specific pulse durations and wavelengths for selective pigment photothermolysis.
Group B: PicoPlus for other dermatological conditions
Subjects receiving PicoPlus laser system treatment for unwanted benign pigmented lesions, melasma or other dermatological conditions such as skin rejuvenation.
PicoPlus laser system
Laser treatment using specific pulse durations and wavelengths for selective pigment photothermolysis.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PicoPlus laser system
Laser treatment using specific pulse durations and wavelengths for selective pigment photothermolysis.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Adults between age 18 and 60 years old
* Group A: Fitzpatrick skin type I - VI for unwanted tattoos and Group B: Fitzpatrick Skin Types I - IV for benign pigmented lesions and other conditions
* Unwanted tattoo that contains single or multi-color ink, and
* Wiling to cover tattoos with a bandage or clothing; and/or have very limited sun exposure and use an approved sunscreen of SPF 50 or higher on the treated area starting 2 to 4 weeks before the treatment
* Ability to read, understand, and sign the Informed Consent Form
* Willing to have digital photographs taken of the treatment area and agree to use of photographs for presentation, educational or marketing purposes.
* Understands and accepts the obligation not to undergo any other procedures in the areas to be treated
* Willing and able to comply with all study participation requirements including returning for follow-up visits and abstaining from exclusionary procedures for the duration of the study
Exclusion Criteria
* If receiving treatment for benign pigmented lesions including melasma: history of use of a lightening medication (hydroquinone, tranexamic acid), isotretinoid (or retinoid), or light-sensitive medication in the last 6 months
* Known cardiovascular disease or cardiac surgery that in the opinion of the investigator would interfere with study treatments
* Previous interventions or treatment with another device in the target area within 6 months of enrollment or during the study
* Pregnant or lactating or planning pregnancy before end of study
* Presence of an active systemic, local skin disease, medication or condition that may affect wound healing or interfere with participation or treatment to the active area.
* Active or recurrent cancer of current chemotherapy or radiation therapy
* History of seizure disorders due to light
* History of vitiligo, eczema, or psoriasis
* History of connective tissue disease, such as systemic lupus erythematosus or scleroderma
* History of pigmentary disorders, particularly tendency for hyper- or hypo-pigmentation
* History of disease stimulated by heat, such as recurrent herpes simplex and/or herpes zoster (shingles) in the treatment area, unless treatment is conducted following a prophylactic regimen
* History of keloid scarring, hypertrophic scarring or of abnormal wound healing.
* History of immunosuppression/immune deficiency disorders or currently using immunosuppressive medications.
* History of seizure disorders due to light.
* Suffering from coagulation disorders or taking prescription anticoagulation medications
* History of keloid scarring, hypertrophic scarring or of abnormal wound healing Any use of medication that is known to increase sensitivity to light according to Investigator's discretion
* Excessive or recent significant tan in areas to be treated or unable/unlikely to refrain from tanning during the study
* Current smoker or history of smoking within 3 months of study participation
* Systemic use of corticosteroid or isotretinoin within 6 months of study participation
* Anytime in life, having have used gold therapy (gold salts) for disorders such as rheumatologic disease or lupus
* Any physical or mental condition including alcohol or drug abuse that in the opinion of the investigator could interfere with subject's suitability for inclusion in study
18 Years
60 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
LUTRONIC Corporation
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kari Larson, MBA
Role: STUDY_DIRECTOR
Sponsor GmbH
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Zena Medical
Newport Beach, California, United States
Metro Dermatology
Elmhurst, New York, United States
Laser and Skin Surgery Center of New York
New York, New York, United States
Dermatology, Laser, and Vein Specialists of the Carolinas
Charlotte, North Carolina, United States
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
L16004
Identifier Type: -
Identifier Source: org_study_id